ASN-FINGOLIMOD CAPSULE
Land: Canada
Språk: engelsk
Kilde: Health Canada
Preparatomtale
(SPC)
18-06-2020
Noen dokumenter for dette produktet er ikke tilgjengelig for øyeblikket, du kan sende en forespørsel til kundeservicen vår, og vi vil varsle deg så snart vi kan få dem.
Send forespørsel.
Send forespørsel.
Aktiv ingrediens:
FINGOLIMOD (FINGOLIMOD HYDROCHLORIDE)
Tilgjengelig fra:
ASCEND LABORATORIES LTD
ATC-kode:
L04AA27
INN (International Name):
FINGOLIMOD
Dosering :
0.5MG
Legemiddelform:
CAPSULE
Sammensetning:
FINGOLIMOD (FINGOLIMOD HYDROCHLORIDE) 0.5MG
Administreringsrute:
ORAL
Enheter i pakken:
100
Resept typen:
Prescription
Terapeutisk område:
Immunomodulatory Agents
Produkt oppsummering:
Active ingredient group (AIG) number: 0152886001; AHFS:
Autorisasjon status:
APPROVED
Autorisasjon dato:
2020-06-23
Preparatomtale
_Page 1 of 64 _
PRODUCT MONOGRAPH
PR
ASN-FINGOLIMOD
Fingolimod capsules
0.5 mg fingolimod capsules (as fingolimod hydrochloride)
Sphingosine 1-phosphate receptor modulator
Ascend Laboratories Ltd.
35 Nixon Road, Unit 10
Caledon, Ontario
L7E 1K1
Date of Approval:
June 18, 2020
Submission Control No: 231582
_Page 2 of 64 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................25
DRUG INTERACTIONS
..................................................................................................33
DOSAGE AND ADMINISTRATION
..............................................................................36
OVERDOSAGE
................................................................................................................39
ACTION AND CLINICAL PHARMACOLOGY
............................................................40
STORAGE AND STABILITY
..........................................................................................45
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................45
PART II: SCIENTIFIC INFORMATION
...............................................................................46
PHARMACEUTICAL INFORMATION
..........................................................................46
CLINICAL TRIALS
..........................................................................................................47
DETAILED PHARMACOLOGY
.................................
Les hele dokumentet
